Glutathione has been found to prevent the signs for aging, and to protect against cancer, heart disease, and dementia
Medical aesthetic patients need to find their treatment at facilities which maintain proper medical standards
Preclinical studies suggest therapeutic potential for strategies targeting EMT transcription factors, signaling pathways, and combination approaches
The system perpetuates itself through a revolving door between regulatory agencies and industry positions, creating networks of influence that shape how therapeutic substances are evaluated, approved, and made available to patients
As of September 2023 it is on the FDA Category 2 list of bulk drug substances that may not be compounded, and a PCAC review is scheduled for July 2026 under the name Emideltide